A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Popular cities in Iowa
Offering a distinguished healthcare infrastructure and top class research institutions, Iowa has emerged as a significant base for a wide range of clinical trials. Major institutions such as the University of Iowa Hospitals and Clinics and the Holden Comprehensive Cancer Center are at the forefront of these studies, driving advancements in fields like oncology, cardiovascular research, and more. Iowa’s commitment to medical innovation and its growing network of research centers make it a developing hub in cutting-edge clinical trials.
Why choose Iowa for clinical trials?
Iowa offers distinct advantages for those participating in clinical trials. The state's distinct population, combined with its strong agricultural and rural communities, provides a diverse range of participants that enhances the accuracy and applicability of research findings. Iowa is also recognized for its innovative research environment and its cutting-edge medical advancements, driven by leading institutions such as the University of Iowa.
By choosing to participate in a clinical trial in Iowa, participants contribute to critical medical research while benefiting from a well-established and supportive clinical research infrastructure that promotes breakthroughs in patient care and treatment.
Common conditions studied in Iowa
Iowa is home to a variety of clinical trials focused on several prominent medical conditions, leveraging the state's strengths in research and healthcare.
Diabetes
Iowa has a significant focus on diabetes, especially Type 2 diabetes, given its high prevalence in both rural and urban areas. Clinical trials in the state often investigate new glucose management strategies, lifestyle interventions, and preventative measures.
Institutions like the Diabetes and Endocrinology Center at the University of Iowa lead research into novel medications, continuous glucose monitoring systems, and educational programs aimed at managing and preventing diabetes. The state's research is crucial for developing tailored approaches that address the lifestyle and dietary factors prevalent in Iowa’s communities.
Cancer
In Iowa, clinical trials are focused on several types of cancer, including breast, lung, and colorectal cancers. The state is home to leading institutions like the Holden Comprehensive Cancer Center at the University of Iowa, which is renowned for its progressive research.
Studies in Iowa often target treatments that consider the unique needs of rural populations, including trials on new drug therapies, targeted therapies, and innovative surgical techniques. The research is vital due to Iowa's high rates of cancer incidence and the need for more effective treatment options tailored to diverse patient demographics.
Interested in learning more about how clinical trials for cancer work? Explore our guide to better understand oncology clinical trials and how they contribute to advancing cancer treatments.
Cardiovascular diseases
Cardiovascular disease research in Iowa addresses conditions such as heart failure, hypertension, and atrial fibrillation. The state’s clinical trials often focus on improving treatment access for its rural population, which faces unique healthcare delivery challenges.
Research includes evaluating new drug therapies, advanced surgical techniques, and lifestyle interventions to manage and prevent heart disease. Institutions like the Iowa Heart Center contribute to this research, aiming to enhance patient outcomes and address the high rates of cardiovascular conditions prevalent in the state.
Respiratory diseases
Clinical trials in Iowa target respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), with particular attention to the impacts of the state's agricultural industry. The exposure to environmental pollutants and allergens makes this research crucial.
Studies here often focus on new inhaler technologies, treatment regimens, and strategies for managing chronic respiratory conditions. The state’s leading research institutions work on developing innovative therapies and interventions to improve quality of life for individuals affected by respiratory issues.
Neurological diseases
Iowa is a key player in neurological research, particularly for Alzheimer’s disease and Parkinson’s disease. Clinical trials in the state explore a range of treatments, from novel drug therapies to cognitive and physical therapies.
Institutions like the University of Iowa Hospitals & Clinics conduct important research into the early detection and management of these conditions. The focus includes evaluating new medications, exploring genetic factors, and developing supportive care strategies to enhance the lives of patients and their families.
Infectious diseases
Infectious disease research in Iowa is prominent, with a strong emphasis on vaccines, antiviral treatments, and combating antibiotic resistance. The state’s agricultural industry drives the need for effective disease prevention and treatment strategies.
Clinical trials often explore new vaccine formulations, treatments for viral infections, and approaches to managing antibiotic-resistant infections. Institutions like the Iowa State University College of Veterinary Medicine play a crucial role in this research, contributing to the development of innovative solutions for both human and animal health.
Local regulations and guidelines
To ensure patient safety and research integrity, clinical trials in Iowa are governed by a combination of federal and state regulations. Trials must adhere to U.S. Food and Drug Administration (FDA) regulations and Good Clinical Practice (GCP) guidelines, with oversight from Institutional Review Boards (IRBs) that review and approve study protocols. The Iowa Department of Public Health also plays a role in overseeing certain research aspects.
Trials must also be registered with ClinicalTrials.gov for transparency, and institutions have their own IRBs and research compliance offices to manage ethical standards and regulatory adherence. Key protections for participants include informed consent requirements and strict privacy safeguards under the Health Insurance Portability and Accountability Act (HIPAA).
Benefits of participating in clinical trials
Participating in a clinical trial offers many advantages, including experiencing advanced treatments and therapies before they are publicly available. This is particularly beneficial for individuals with conditions that have not improved with standard treatments. Participants receive high-quality care from skilled medical professionals who provide rigorous monitoring and personalized support throughout the study.
In addition to the direct benefits of early access to innovative care, involvement in clinical trials is crucial for the advancement of medical science. Successful trials can lead to significant breakthroughs in treatments and therapies. By joining a trial, individuals not only benefit personally but also contribute to the progress of medical research, ultimately helping to improve healthcare outcomes for future patients.
How to enroll in a clinical trial in Iowa
Enrolling in a clinical trial through our platform is a straightforward and user-friendly process. Here's how to get started:
- Identify your trial: Use our intuitive search bar or filter options to locate clinical trials specific to requirements. This first step simplifies the process of finding relevant research studies tailored to your needs.
- Select your preferred location: To find trials conveniently located near you, simply input your preferred location into the dedicated filter bar on the left-hand side of the page.
- Explore study details: For in-depth information about each study, simply click the “Learn More” button. This will provide you with comprehensive details about the trial, including objectives, procedures, and eligibility criteria.
- Complete the health profile: After clicking on the “Get started” button you will be taken to our efficient 5-step application process to provide important health information. This helps us match you with the clinical trial that best fits your needs.
- Submit the application: After completing the application, send it in. A clinical trial coordinator will review it and contact you regarding the possibility of participation.